Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Belgium

Marie Skłodowska-Curie Action · Running

GUT-MicroMaP Gut-on-chip Utilization for Therapeutic design: Microbiome-epithelium interactions Model And Predictions

Coordinator
Katholieke Universiteit Leuven, Belgium
Runs
1 August 2027 to 31 July 2029
Status
Running
EU funding
€216k
Total cost
—
Partners
3 organisations in 3 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101275703

What the project is doing

In the project's own words, from its summary on CORDIS.

The gut epithelium is a dynamic interface where microbial metabolism, mucus structure, and mechanical cues jointly determine barrier function and disease susceptibility. Conventional approaches—such as fecal omics, animal models, and static Transwells—either lack human relevance or the spatiotemporal control required for predictive modeling and therapeutic design. Gut-on-chip devices have recently emerged as powerful tools to bridge this gap, reproducing key features of the human intestine, including oxygen gradients, peristaltic-like flow, mucus layers, and co-culture with anaerobic microbial consortia.

These systems enable causal experiments under controlled regimes, yet their use has remained largely descriptive, and no predictive computational framework exists to generalize experimental results or guide rational intervention strategies. GUT-MicroMaP addresses this gap by developing and validating the first rigorously calibrated, spatially explicit mathematical model of microbiome–epithelium interactions in gut-on-chip systems.

The project will integrate high-resolution spatial multi-omics data from the 3D’omics consortium with hybrid PDE–ABM–CFD modeling to create a digital twin of the gut environment. This model will capture microbial motility, adhesion, and biofilm dynamics under metabolites and mucus conditions, and will be iteratively refined through Bayesian calibration and sensitivity analysis. Once validated, it will serve as an in-silico platform to design microbiome-directed therapeutic strategies—including prebiotics, probiotics, and phage therapies—optimizing barrier integrity while suppressing pathogens.

Therapeutic insights will integrate sex/gender variability in gut physiology and immunity, ensuring broader relevance and equity. By merging spatial omics with advanced modeling, GUT-MicroMaP will deliver a transformative predictive framework for gut health, opening new avenues for rational therapeutic design in microbiome research.

Topics

Who is involved

OrganisationCityCountryRole
Katholieke Universiteit LeuvenLeuvenBelgiumCoordinator
Kobenhavns UniversitetKobenhavnDenmarkAssociatedpartner
The University of BirminghamBirminghamUnited KingdomAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS